- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules ×
- Software & Information Technology
- Stem Cells
- Vaccines
- Veterinary Medicine
Isolated organ viral, theraputic or cell therapy delivery
Value proposition Cardiovascular diseases (CVD) remain the leading cause of death worldwide. The number of CVD patients with heart failure (HF) in the US is approaching 6.5 million adults and is estimated to increase by…
Enhancing of homing and/or engraftment of cord blood mononuclear cells in the central nervous system
Value Proposition Leukodystrophies are inherited disorders resulting in decreased motor function, muscle rigidity, degeneration of sight and hearing, and are ultimately fatal. There is a great lack of treatment, although cord blood mononuclear (CBM) and…
Diagnostic and treatment for chronic and acute phase myeloid leukemia
Value Proposition While cancer therapies have increased survival for many tumor types, the reality is that 50-60% of cancer patients will die from the disease. This highlights a need for the continued search for targeted…
Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer
Value Proposition One in twelve men will be diagnosed with prostate cancer in their lifetime. Castration resistant prostate cancer, which resists traditional hormone therapies and continues to grow and often metastasize with poor survival outcomes,…
SUMO as a marker of cancer development and target for cancer therapy
Value Proposition Cancer therapy remains challenging, and the production of new inhibitor therapies is stinted by the need for clear successful targets that will block tumor cell proliferation. Small ubiquitin-like modifier (SUMO) proteins and the…